Ipragliflozin a sodium–glucose cotransporter 2 inhibitor reduces bodyweight and fat mass but not muscle mass in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

摘要

Aims/IntroductionSodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cotransporter 2 inhibitors on BW and body composition remain unclear. We examined these effects in Japanese patients with type 2 diabetes mellitus treated with insulin.